JP5860047B2 - Fshの安定化 - Google Patents

Fshの安定化 Download PDF

Info

Publication number
JP5860047B2
JP5860047B2 JP2013521146A JP2013521146A JP5860047B2 JP 5860047 B2 JP5860047 B2 JP 5860047B2 JP 2013521146 A JP2013521146 A JP 2013521146A JP 2013521146 A JP2013521146 A JP 2013521146A JP 5860047 B2 JP5860047 B2 JP 5860047B2
Authority
JP
Japan
Prior art keywords
rfsh
fsh
salt
formulation
hcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013521146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532677A5 (cg-RX-API-DMAC7.html
JP2013532677A (ja
Inventor
ウルリカ シェーグレン,ヘレン
ウルリカ シェーグレン,ヘレン
ルイーセ バッガー,ハイジ
ルイーセ バッガー,ハイジ
Original Assignee
フェリング ベスローテン フェンノートシャップ
フェリング ベスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェリング ベスローテン フェンノートシャップ, フェリング ベスローテン フェンノートシャップ filed Critical フェリング ベスローテン フェンノートシャップ
Publication of JP2013532677A publication Critical patent/JP2013532677A/ja
Publication of JP2013532677A5 publication Critical patent/JP2013532677A5/ja
Application granted granted Critical
Publication of JP5860047B2 publication Critical patent/JP5860047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013521146A 2010-07-30 2011-07-28 Fshの安定化 Active JP5860047B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10171428.5 2010-07-30
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
PCT/EP2011/062986 WO2012013742A2 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015245748A Division JP2016102127A (ja) 2010-07-30 2015-12-17 Fshの安定化

Publications (3)

Publication Number Publication Date
JP2013532677A JP2013532677A (ja) 2013-08-19
JP2013532677A5 JP2013532677A5 (cg-RX-API-DMAC7.html) 2014-09-11
JP5860047B2 true JP5860047B2 (ja) 2016-02-16

Family

ID=43216624

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013521146A Active JP5860047B2 (ja) 2010-07-30 2011-07-28 Fshの安定化
JP2015245748A Pending JP2016102127A (ja) 2010-07-30 2015-12-17 Fshの安定化
JP2017212395A Active JP6522711B2 (ja) 2010-07-30 2017-11-02 Fshの安定化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015245748A Pending JP2016102127A (ja) 2010-07-30 2015-12-17 Fshの安定化
JP2017212395A Active JP6522711B2 (ja) 2010-07-30 2017-11-02 Fshの安定化

Country Status (27)

Country Link
US (3) US8993732B2 (cg-RX-API-DMAC7.html)
EP (3) EP2417982A1 (cg-RX-API-DMAC7.html)
JP (3) JP5860047B2 (cg-RX-API-DMAC7.html)
KR (2) KR101991756B1 (cg-RX-API-DMAC7.html)
CN (2) CN103052398B (cg-RX-API-DMAC7.html)
AR (1) AR082776A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011284702C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013002312B1 (cg-RX-API-DMAC7.html)
CA (1) CA2805864A1 (cg-RX-API-DMAC7.html)
DK (1) DK2598160T3 (cg-RX-API-DMAC7.html)
ES (1) ES2623634T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170386T1 (cg-RX-API-DMAC7.html)
HU (1) HUE033592T2 (cg-RX-API-DMAC7.html)
IL (2) IL223821A (cg-RX-API-DMAC7.html)
JO (1) JO3229B1 (cg-RX-API-DMAC7.html)
LT (1) LT2598160T (cg-RX-API-DMAC7.html)
MX (2) MX356951B (cg-RX-API-DMAC7.html)
NZ (2) NZ606366A (cg-RX-API-DMAC7.html)
PL (1) PL2598160T3 (cg-RX-API-DMAC7.html)
PT (1) PT2598160T (cg-RX-API-DMAC7.html)
RS (1) RS55772B1 (cg-RX-API-DMAC7.html)
RU (1) RU2574012C2 (cg-RX-API-DMAC7.html)
SA (1) SA114350786B1 (cg-RX-API-DMAC7.html)
SI (1) SI2598160T1 (cg-RX-API-DMAC7.html)
TW (1) TWI439283B (cg-RX-API-DMAC7.html)
WO (1) WO2012013742A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209497B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018048188A (ja) * 2010-07-30 2018-03-29 フェリング ベスローテン フェンノートシャップ Fshの安定化

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
MX356383B (es) * 2013-11-12 2018-05-24 Cadila Healthcare Ltd Formulación líquida de gonadotropina estabilizada con polietilenglicol.
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN111836616B (zh) 2017-12-07 2024-01-16 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph 7为7的可注射溶液
BR112020011570A2 (pt) 2017-12-07 2020-12-08 Adocia Solução injetável a um ph 7 compreendendo pelo menos uma insulina basal apresentando um pi entre 5,8 e 8,5 e um co-poliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたhmgb1含有溶液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA61053C2 (en) 1995-03-21 2003-11-17 Applied Research Systems Stable liquid pharmaceutical compositions, method for its production and delivery form
AU738176B2 (en) * 1996-05-29 2001-09-13 Delsitech Oy Dissolvable oxides for biological applications
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
KR20010083126A (ko) * 1998-07-23 2001-08-31 피터 지. 스트링거 여포자극 호르몬 및 여포자극 호르몬 변이체 제형, 제품및 방법
MXPA06011029A (es) * 2004-04-07 2007-01-25 Ares Trading Sa Formulacion liquida de hormona del crecimiento.
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
SI2249869T1 (sl) * 2008-02-08 2012-01-31 Biogenerix Ag Tekoäśa formulacija fsh
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
MX2011013898A (es) * 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018048188A (ja) * 2010-07-30 2018-03-29 フェリング ベスローテン フェンノートシャップ Fshの安定化

Also Published As

Publication number Publication date
AU2011284702B2 (en) 2015-05-14
US8993732B2 (en) 2015-03-31
MX2013000681A (es) 2013-02-27
CN103052398B (zh) 2015-09-16
US20150265681A1 (en) 2015-09-24
US20130210727A1 (en) 2013-08-15
AR082776A1 (es) 2013-01-09
SI2598160T1 (sl) 2017-07-31
MX356951B (es) 2018-06-21
AU2011284702A1 (en) 2013-02-07
ZA201209497B (en) 2013-08-28
US20170216405A1 (en) 2017-08-03
EP2417982A1 (en) 2012-02-15
JP6522711B2 (ja) 2019-05-29
RS55772B1 (sr) 2017-07-31
US9463221B2 (en) 2016-10-11
EP2598160A2 (en) 2013-06-05
SA114350786B1 (ar) 2015-07-09
CA2805864A1 (en) 2012-02-02
JO3229B1 (ar) 2018-03-08
BR112013002312B1 (pt) 2021-09-21
RU2574012C2 (ru) 2016-01-27
NZ606366A (en) 2014-08-29
JP2013532677A (ja) 2013-08-19
IL249920A0 (en) 2017-03-30
EP2598160B1 (en) 2017-02-22
KR101820115B1 (ko) 2018-01-18
MX341464B (es) 2016-08-22
KR101991756B1 (ko) 2019-06-21
HRP20170386T1 (hr) 2017-05-05
EP3144010A1 (en) 2017-03-22
AU2011284702C1 (en) 2015-09-03
KR20180008916A (ko) 2018-01-24
CN103052398A (zh) 2013-04-17
JP2018048188A (ja) 2018-03-29
IL223821A (en) 2017-01-31
RU2012157154A (ru) 2014-09-10
LT2598160T (lt) 2017-04-10
JP2016102127A (ja) 2016-06-02
WO2012013742A3 (en) 2012-04-19
PL2598160T3 (pl) 2017-06-30
TWI439283B (zh) 2014-06-01
ES2623634T3 (es) 2017-07-11
TW201208694A (en) 2012-03-01
KR20130143692A (ko) 2013-12-31
HUE033592T2 (hu) 2017-12-28
WO2012013742A2 (en) 2012-02-02
DK2598160T3 (en) 2017-03-27
PT2598160T (pt) 2017-03-30
NZ628962A (en) 2016-01-29
BR112013002312A2 (pt) 2018-03-20
CN105106939A (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
JP5860047B2 (ja) Fshの安定化
US20250352621A1 (en) Stable liquid gonadotropin formulation
HK1184381B (en) Stabilization of fsh
HK1184381A (en) Stabilization of fsh

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151217

R150 Certificate of patent or registration of utility model

Ref document number: 5860047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250